BMS-345541
BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice. It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1286499933 under CC BY-SA 4.0; modifications have been made.